ImmuPharma (LON:IMM) Trading Up 27.3% - Here's Why

Key Points

• ImmuPharma's stock surged by 27.3% during trading on Friday, reaching a high of GBX 12.75 ($0.17) after closing at GBX 9.90 ($0.13) the previous day.
• The company has a market capitalization of £63.34 million and a negative P/E ratio of -1,415.73, indicating significant financial challenges.
• ImmuPharma is focused on developing peptide-based therapeutics for autoimmune diseases, with its lead program targeting Lupus through a mechanism known as autophagy.

ImmuPharma plc (LON:IMM - Get Free Report) was up 27.3% during trading on Friday . The company traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Price Performance

The company has a market capitalization of £63.34 million, a P/E ratio of -1,415.73 and a beta of 1.53. The company has a fifty day moving average price of GBX 7.70 and a two-hundred day moving average price of GBX 4.29.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.